Replimune Group Inc
(NAS:REPL)
$
10.105
0.115 (1.15%)
Market Cap: 690.39 Mil
Enterprise Value: 291.75 Mil
PE Ratio: 0
PB Ratio: 1.62
GF Score: 33/100 - Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Replimune Group Inc RP1 Program Update Call TranscriptDec 05, 2023
- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Replimune Group Inc to Host Virtual Investor Event TranscriptDec 07, 2022
- Replimune Group Inc To Host Investor Day TranscriptMar 30, 2022
- Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Replimune Group Inc Annual Shareholders Meeting TranscriptSep 08, 2021
- Replimune Group Inc Virtual Investor Event Corporate Call TranscriptJun 03, 2021
- Replimune Group Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Replimune Group Inc to Provide Phase 1/2 Clinical Data Update on Patients with Melanoma and Non-Melanoma Skin Cancers - Conference Call TranscriptJun 03, 2020
- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020 / 01:00AM GMT
Release Date Price:
$18.27
(+1.61%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst
Start?
Philip Astley;Sparke
Replimune Group, Inc. - Chairman, CEO, Secretary & Treasurer
Yes.
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst
Okay. So welcome to the Tuesday afternoon session of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Replimune, and presenting on behalf of the company is CEO, Philip Astley-Sparke.
Philip Astley;Sparke
Replimune Group, Inc. - Chairman, CEO, Secretary & Treasurer
Thanks, Anupam. Safe harbor. So Replimune. Replimune was founded in 2015 to realize the full potential of oncolytic immunotherapy. We believe that our products become the second cornerstone of immuno-oncology. Our lead asset, RP1, primarily focuses on immuno-responsive
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)